140 related articles for article (PubMed ID: 37235783)
1. Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports.
Bouraima F; Sapin V; Kahouadji S; Pickering ME; Pereira B; Bouvier D; Oris C
J Clin Endocrinol Metab; 2023 Oct; 108(11):3031-3040. PubMed ID: 37235783
[TBL] [Abstract][Full Text] [Related]
2. Hypophosphatemia related to a neuro-endocrine tumor of the pancreas: A case report.
Pickering ME; Bouvier D; Puravet A; Soubrier M; Sapin V; Oris C
Clin Biochem; 2022 Jun; 104():62-65. PubMed ID: 35337828
[TBL] [Abstract][Full Text] [Related]
3. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.
Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P
J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases.
Bosman A; Palermo A; Vanderhulst J; De Beur SMJ; Fukumoto S; Minisola S; Xia W; Body JJ; Zillikens MC
Calcif Tissue Int; 2022 Oct; 111(4):367-379. PubMed ID: 35857061
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.
Leaf DE; Pereira RC; Bazari H; Jüppner H
J Clin Endocrinol Metab; 2013 Mar; 98(3):887-91. PubMed ID: 23393166
[TBL] [Abstract][Full Text] [Related]
6. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia.
Abate V; Vergatti A; De Filippo G; Damiano V; Menale C; D'Elia L; Rendina D
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1006-e1011. PubMed ID: 38006315
[TBL] [Abstract][Full Text] [Related]
9. Tumor-induced osteomalacia: experience from a South American academic center.
González G; Baudrand R; Sepúlveda MF; Vucetich N; Guarda FJ; Villanueva P; Contreras O; Villa A; Salech F; Toro L; Michea L; Florenzano P
Osteoporos Int; 2017 Jul; 28(7):2187-2193. PubMed ID: 28341900
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Induced Osteomalacia With Normal Fibroblast Growth Factor-23 (FGF23) and Idiopathic Hypercalciuria.
Velazquez-Navarro JA; Loya-Teruel E; Rios-Gomez M; Montes-Ramirez JE
Cureus; 2022 Jan; 14(1):e20893. PubMed ID: 35145798
[TBL] [Abstract][Full Text] [Related]
11. Tumour-induced osteomalacia: a literature review and a case report.
Dadoniene J; Miglinas M; Miltiniene D; Vajauskas D; Seinin D; Butenas P; Kacergius T
World J Surg Oncol; 2016 Jan; 14(1):4. PubMed ID: 26744291
[TBL] [Abstract][Full Text] [Related]
12. Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Abramson M; Glezerman IG; Srinivasan M; Ross R; Flombaum C; Gutgarts V
Clin Nephrol; 2021 Feb; 95(2):104-111. PubMed ID: 33191899
[TBL] [Abstract][Full Text] [Related]
13. The genetic polymorphisms of XPR1 and SCL34A3 are associated with Fanconi syndrome in Chinese patients of tumor-induced osteomalacia.
Jiang Y; Li X; Feng J; Li M; Wang O; Xing XP; Xia WB
J Endocrinol Invest; 2021 Apr; 44(4):773-780. PubMed ID: 32725396
[TBL] [Abstract][Full Text] [Related]
14. Prolonged Hypophosphatemia and Intensive Care After Curative Surgery of Tumor Induced Osteomalacia: A Case Report.
Ryhänen EM; Schalin-Jäntti C; Matikainen N
Front Endocrinol (Lausanne); 2021; 12():686135. PubMed ID: 34149623
[TBL] [Abstract][Full Text] [Related]
15. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23.
Nasu T; Kurisu S; Matsuno S; Tatsumi K; Kakimoto T; Kobayashi M; Nakano Y; Wakasaki H; Furuta H; Nishi M; Sasaki H; Suzuki H; Ito N; Fukumoto S; Nanjo K
Intern Med; 2008; 47(10):957-61. PubMed ID: 18480582
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the management of tumor-induced osteomalacia (TIO).
Brandi ML; Clunie GPR; Houillier P; Jan de Beur SM; Minisola S; Oheim R; Seefried L
Bone; 2021 Nov; 152():116064. PubMed ID: 34147708
[TBL] [Abstract][Full Text] [Related]
17. Tumor-induced Osteomalacia: A Systematic Review and Individual Patient's Data Analysis.
Rendina D; Abate V; Cacace G; D'Elia L; De Filippo G; Del Vecchio S; Galletti F; Cuocolo A; Strazzullo P
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3428-e3436. PubMed ID: 35468192
[TBL] [Abstract][Full Text] [Related]
18. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
19. Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series.
Cianferotti L; Delli Poggi C; Bertoldo F; Caffarelli C; Crotti C; Gatti D; Giannini S; Gonnelli S; Mazzantini M; Ombretta V; Sella S; Setti A; Varenna M; Zucchi F; Brandi ML
Endocrine; 2022 Jun; 76(3):709-721. PubMed ID: 35381903
[TBL] [Abstract][Full Text] [Related]
20. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.
Mori Y; Ogasawara T; Motoi T; Shimizu Y; Chikazu D; Tamura K; Fukumoto S; Takato T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):e57-63. PubMed ID: 20219587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
